Market Place
Sourcing Support
Qpex Biopharma Awarded 10M By BARDA For Antibiotic Portfolio
30 May 2024 //
BUSINESSWIRE
Shionogi Extends Infectious Disease Innovation Platform with Acquisition of Qpex
26 Jun 2023 //
BUSINESSWIRE
Brii Bio Announces Agreements with Qpex & Acquiring Global Rights for BRII-693
25 Jun 2023 //
PR NEWSWIRE
Qpex to Present PhI & Nonclinical Data on 3 Clinical Stage Oral & IV Products
17 Oct 2022 //
BUSINESSWIRE
Qpex Announces Presentation of Clinical Data for Ultra-Broad Spectrum ?
21 Apr 2022 //
BUSINESSWIRE
Qpex Biopharma Announces Publication of Data in Nature Communications on QPX9003
30 Mar 2022 //
BUSINESSWIRE
Qpex Biopharma: Progress on 3 Programs for Antibiotic-Resistant Pathogens
19 Jan 2022 //
BUSINESSWIRE
Qpex Initiates Phase 1 Study of QPX9003 Targeting Antibiotic-Resistant Pathogens
17 Jun 2021 //
BUSINESSWIRE
Qpex Biopharma Initiates Phase 1 Study of QPX9003
16 Jun 2021 //
BUSINESSWIRE
Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral
12 May 2021 //
BUSINESSWIRE
Qpex Biopharma Initiates Ph1 Study of ORAvance
12 May 2021 //
BIOSPACE
Qpex Biopharma Strengthens Leadership Team and Provides Update on BARDA Award
05 Jan 2021 //
BUSINESSWIRE
Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant
03 Dec 2020 //
BUSINESSWIRE
Qpex Biopharma, Brii Biosciences Ink Anti-infective Alliance
22 Oct 2019 //
CONTRACTPHARMA
Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University
30 Apr 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.